Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 15/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16472337 | 1.00 | OGA (0.38) | OGAGLSCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9918330 | 1.00 | OGA (0.38) | OGAGLSCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9920471 | 0.84 | OGA (0.42) | OGA | |
| SCHEMBL9923207 | 0.84 | OGA (0.42) | OGA | |
| SCHEMBL14790984 | 0.83 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16587726 | 0.83 | PANK3 (0.42) | — | |
| SCHEMBL18291177 | 0.79 | GLS (0.39) | GLSCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18291191 | 0.79 | PTPN11 (0.39) | OGAGLSCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12832913 | 0.77 | GRIN2D (0.40) | OGA | |
| SCHEMBL18890104 | 0.75 | HRH4 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | OGA 4825/4885GLS 1561/4885CHRNB2 4866/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | OGA 4487/4885GLS 2420/4885CHRNB2 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.